Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V

被引:21
作者
Noack, F
Sotlar, K
Notter, M
Thiel, E
Valent, P
Horny, HP
机构
[1] Med Univ Lubeck, Dept Pathol, D-23538 Lubeck, Germany
[2] Univ Tubingen, Dept Pathol, Tubingen, Germany
[3] Univ Hosp Benjamin Franklin, Dept Hematol Oncol & Transfus Med, Berlin, Germany
[4] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
关键词
CD2; CD25; CD68; c-kit mutation; mastocytosis; mast cell leukemia;
D O I
10.1080/10428190412331272695
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mastocytosis comprises a heterogeneous group of disorders characterized by proliferation and accumulation of mast cells in 1 or more organ systems. Mast cell leukemia (MCL) is an extremely rare subtype of mastocytosis in which a leukemic spread of mast cells and a rapid progression of disease is seen. In typical cases, mast cells are found in the peripheral blood. However, an aleukemic variant of MCL (formerly termed malignant mastocytosis) has also been described. We here report a case of aleukemic MCL with abnormal immunophenotype of mast cells and the classical c-kit point mutation Asp-816-Val (=D816V). The 75-year-old male patient had a short history of weight loss and lymphadenopathy. There were no urticaria pigmentosa-like skin lesions. The bone marrow was diffusely infiltrated with atypical mast cells that comprised more than 80% of all nucleated cells on a bone marrow smears. As assessed by immunohistochemistry, neoplastic mast cells expressed tryptase, chymase, CD2, CD25, CD68, and the KIT protein (CD117). Mutation analysis revealed the c-kit mutation D816V. Since circulating mast cells could not be detected in the peripheral blood, the diagnosis of aleukemic MCL was established in accordance to the updated WHO consensus classification. This case further supports the notion that the pathogenesis (c-kit mutation D816V) in MCL is closely related to that found in indolent mast cell disorders. However, additional (but yet unknown) molecular (genetic) defects have to be considered to explain the extremely heterogenous clinical course in these patients.
引用
收藏
页码:2295 / 2302
页数:8
相关论文
共 46 条
[1]   Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit [J].
Akin, C ;
Brockow, K ;
D'Ambrosio, C ;
Kirshenbaum, AS ;
Ma, YS ;
Longley, BJ ;
Metcalfe, DD .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) :686-692
[2]  
Baghestanian M, 1996, LEUKEMIA, V10, P159
[3]   c-Kit and c-kit mutations in mastocytosis and other hematological diseases [J].
Boissan, M ;
Feger, F ;
Guillosson, JJ ;
Arock, M .
JOURNAL OF LEUKOCYTE BIOLOGY, 2000, 67 (02) :135-148
[4]  
BRINKMANN E, 1959, Schweiz Med Wochenschr, V89, P1046
[5]   ESTABLISHMENT OF AN IMMATURE MAST-CELL LINE FROM A PATIENT WITH MAST-CELL LEUKEMIA [J].
BUTTERFIELD, JH ;
WEILER, D ;
DEWALD, G ;
GLEICH, GJ .
LEUKEMIA RESEARCH, 1988, 12 (04) :345-355
[6]   Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation [J].
Chen, TY ;
Chen, JS ;
Huang, WT ;
Su, WC ;
Tsao, CJ .
BONE MARROW TRANSPLANTATION, 2003, 32 (01) :111-114
[7]  
CLANCY RL, 1976, CANCER, V37, P693, DOI 10.1002/1097-0142(197602)37:2<693::AID-CNCR2820370213>3.0.CO
[8]  
2-X
[9]   CYTOBIOLOGICAL AND CLINICAL ASPECTS OF TISSUE MAST-CELL LEUKEMIA [J].
COSER, P ;
QUAGLINO, D ;
DEPASQUALE, A ;
COLOMBETTI, V ;
PRINOTH, O .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 45 (01) :5-&
[10]   MAST-CELL LEUKEMIA - EVIDENCE FOR BONE-MARROW ORIGIN OF THE PATHOLOGICAL CLONE [J].
DALTON, R ;
CHAN, L ;
BATTEN, E ;
ERIDANI, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (02) :397-406